



Nicox's Ordinary Shareholder Meeting

June 7, 2013.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) has convened an Ordinary shareholder meeting on a second call and on same agenda on **Thursday June 20, 2013 at 2:00 pm CET** at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis, the quorum was not reached on the first call on June 6, 2013.

The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French *Code de commerce*, will be sent to shareholders upon written request. These documents are also available to shareholders at the headquarters and on the website of the Company (www.nicox.com).



About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sized international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus™, a test for the differential diagnosis of acute conjunctivitis in-licensed from RPS®.

The Company's pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada).

Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Small Caps). For more information please visit www.nicox.com.

This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous

risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).



Contact:

Nicox Communications Corporate

Tel +33 (0)4 97 24 53 00 | communications@nicox.com